Business Wire

IL-NIQ

7.2.2024 13:01:35 CET | Business Wire | Press release

Share
NIQ Unveils Comprehensive 2024 Consumer Outlook Report: Navigating Global Trends and Insights for Strategic Growth

NIQ, a leading authority in consumer intelligence, proudly announces the release of its highly anticipated 2024 Global Consumer Outlook Report. This comprehensive document explores critical trends and insights that shape the consumer landscape, delivering invaluable data and analysis for businesses and stakeholders worldwide.

Navigating the intricate global economic terrain, the report delves into the repercussions of significant economic events and trends, shedding light on their impact on consumer confidence and spending behavior. Moving beyond a broad overview, the analysis explores regional variances, providing in-depth insights into the unique dynamics of Asia Pacific, Europe, North America, Africa, the Middle East, and Latin America. This bi-annual thought leadership study uncovers nuances in consumer preferences and changes in consumer attitudes and purchasing patterns, empowering retailers and manufacturers with a strategic understanding of their target markets to facilitate the formulation of tailored strategies for sustainable growth.

"In today's disruptive global economy, our Consumer Outlook Report for 2024 serves as a compass, navigating through the ripples of economic events and unveiling insights into consumer behavior,” said Tracey Massey, COO of NIQ. “As businesses confront the challenges of a changing landscape, this report equips them with strategic foresight, offering a tailored understanding of regional variances and empowering them to steer their course toward sustainable growth."

Key findings from the NIQ Global Consumer Outlook Report:

  • Value and Volume Slowdown: In November 2023, prices rose by 6.1%, a significant drop from the 13.6% increase observed in January 2023. As inflation decelerates, it reveals that the slowed growth in sales value no longer masks low or declining consumption rates. Retailers and brands must strategically respond to avert excessive promotions and safeguard the bottom line.
  • Consumers Under Pressure: Today, 34% of global consumers feel worse off financially than a year ago, as the unemployment rate remains steady and wages lag inflation. As the global crisis remains top-of-mind, expect increased competition for a smaller share of consumer spending.
  • Proactive and Precise with Wellness: 40% of global consumers proactively prioritize their health, contributing to a growth niche in the market. Recognizing the significance of proactive health management, consumers are keen on specific lifestyle changes and product features to attain their health goals.
  • Hybrid Views on Value: In a custom analysis across different price tiers, value-priced products were the only group to see sales share growth (0.6 pts) in 2023. Financial polarization between affluent and vulnerable consumers drives an expanded search for value options, and retailers and manufacturers should anticipate demand for new affordable product assortments in 2024.
  • Value-focused Innovation Growth: Manufacturers that innovate are 1.8 times more likely to boost overall sales. Continuous innovation has proven most advantageous for companies amid market slowdowns. Innovation isn't limited to premium positioning; companies must pursue value-driven initiatives to thrive.
  • Fluid Channel Dynamics: 11% of global consumers report shopping through social media channels. As the retail landscape evolves, adapting to changing patterns in how consumers explore, experiment with, and purchase products is crucial.

"The Global Consumer Outlook Report illuminates not just trends but critical shifts in consumer preferences and buying patterns, transcending borders and encompassing regions from North America to Asia Pacific,” said Lauren Fernandes, Global Director of Thought Leadership, NIQ. “From the ebb and flow of value and volume to the hybrid views on value, this report provides businesses with a comprehensive toolkit to adapt, innovate, and thrive in an environment marked by change. It's not just a report; it's a guide for businesses seeking resilience and relevance in an ever-shifting market."

NIQ’s commitment to delivering actionable insights is evident in the research and analysis presented in the Consumer Outlook Report. This valuable resource empowers businesses to make informed decisions in an ever-evolving consumer landscape. Download the report today.

About NIQ

NIQ is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. In 2023, NIQ combined with GfK, bringing together the two industry leaders with unparalleled global reach. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full ViewTM.

NIQ is an Advent International portfolio company with operations in 100+ markets, covering more than 90% of the world’s population. For more information, visit NIQ.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240207415974/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye